NCX 4251 may be effective at reducing dry eye disease symptoms in a specific subgroup of patients, according to a press release from Nicox.
NCX 4251(fluticasone propionate ophthalmic suspension 0.1%) failed to meet primary or secondary efficacy endpoints in the phase 2b Mississippi clinical trial, but it may have a path forward following a post hoc analysis of the study results.
In a subgroup of patients with baseline scores of 2 or greater on a scale of 0 to 4 for inferior cornea fluorescein staining, the post hoc analysis showed (Read more...)